Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
07
2018
accepted:
18
10
2018
entrez:
9
2
2019
pubmed:
9
2
2019
medline:
30
5
2019
Statut:
epublish
Résumé
TIGIT is an inhibitory immune checkpoint receptor and a putative target for novel immune therapies. Here, we analysed two different types of tissue microarrays of healthy lymphatic and various inflamed tissues, colorectal and lung cancers, as well as >1700 tumour samples from 86 different tumour entities for TIGIT and/or PD-1 by bright field and/or multiplex fluorescence immunohistochemistry. TIGIT was detected in CD8
Identifiants
pubmed: 30733837
doi: 10.1155/2019/5160565
pmc: PMC6348838
doi:
Substances chimiques
Receptors, Immunologic
0
TIGIT protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5160565Références
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Eur J Immunol. 2009 Mar;39(3):695-703
pubmed: 19197944
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
J Exp Med. 2010 Sep 27;207(10):2175-86
pubmed: 20819923
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
J Immunol. 2011 Feb 1;186(3):1338-42
pubmed: 21199897
Eur J Immunol. 2011 Apr;41(4):902-15
pubmed: 21416464
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
J Immunol. 2012 Apr 15;188(8):3869-75
pubmed: 22427644
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Cancer Res. 2012 Oct 15;72(20):5159-64
pubmed: 22826606
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Curr HIV Res. 2013 Dec;11(8):595-600
pubmed: 24568615
Immunity. 2014 Apr 17;40(4):569-81
pubmed: 24745333
Cancer J. 2014 Jul-Aug;20(4):265-71
pubmed: 25098287
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800
Cancer Cell. 2014 Dec 8;26(6):785-787
pubmed: 25490444
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Nature. 2015 Jan 1;517(7532):109-10
pubmed: 25557714
Arthritis Res Ther. 2014;16(5):469
pubmed: 25606596
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
Cell Rep. 2015 Jun 23;11(11):1822-33
pubmed: 26074076
Eur J Immunol. 2015 Oct;45(10):2886-97
pubmed: 26171588
Cancer Biol Med. 2015 Jun;12(2):74-8
pubmed: 26175922
J Clin Invest. 2015 Nov 2;125(11):4053-62
pubmed: 26413872
Clin Cancer Res. 2016 Jun 15;22(12):3057-66
pubmed: 26763253
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Nat Med. 2016 Jul;22(7):754-61
pubmed: 27239760
Curr Opin Immunol. 2016 Aug;41:23-31
pubmed: 27240055
Front Immunol. 2016 Jun 16;7:221
pubmed: 27379090
Clin Cancer Res. 2016 Nov 1;22(21):5183-5188
pubmed: 27620276
Trends Immunol. 2017 Jan;38(1):20-28
pubmed: 27793572
Immunol Invest. 2017 Feb;46(2):172-182
pubmed: 27819527
Front Immunol. 2016 Nov 22;7:522
pubmed: 27920778
Cell Res. 2017 Jan;27(1):11-37
pubmed: 28025978
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
Nat Biotechnol. 2017 Jun 7;35(6):487-488
pubmed: 28591107
Thyroid. 2017 Oct;27(10):1335-1336
pubmed: 28699391
Cell. 2017 Sep 7;170(6):1055-1056
pubmed: 28886376
Curr Allergy Asthma Rep. 2017 Sep 27;17(10):72
pubmed: 28956259
Front Immunol. 2017 Sep 29;8:1215
pubmed: 29033936
J Endocrinol Invest. 2018 May;41(5):549-556
pubmed: 29043574
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
Oncol Rep. 2018 Jan;39(1):3-12
pubmed: 29115542
Clin Cancer Res. 2018 Feb 15;24(4):870-881
pubmed: 29217528
Oncotarget. 2018 Jan 2;9(6):6841-6851
pubmed: 29467933
Oncol Lett. 2018 May;15(5):6457-6468
pubmed: 29616115
Sci Rep. 2018 May 10;8(1):7485
pubmed: 29748589